KYNTRA BIO, INC. business relationships
Companies named in KYNTRA BIO, INC.’s 10-K filed 2026-03-16, and public companies whose annual reports name KYNTRA BIO, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.0 / 10
- AI naming
- <1 / 100 Top 49% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in KYNTRA BIO, INC.’s annual report 9
“Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas in support of pre-commercial preparation prior to the New Drug Application ("NDA") or Marketing Authorization Application approval, and to Astellas for ongoing commercial activities in Japan and...” SEC filing
“...ction price: The gross transaction price is based on a percentage of Falikang's net sales to its distributors, which takes into account Falikang's operating expenses and its payments to AstraZeneca for roxadustat sales and marketing efforts, capped at a percentage of Falikang's net roxadustat sales.” SEC filing
“Kyntra Bio has retained the rights to roxadustat in the U.S., Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas.” SEC filing
“Amounts of the transaction price allocable to this performance obligation under the Company's agreements with AstraZeneca as outlined in Note 4, Collaboration Agreements, License Agreement and Revenues, are deferred until control of the manufactured commercial product is transferred to AstraZeneca.” SEC filing
“$1.8 million of development revenue recognized under our collaboration agreements with our partners Astellas and AstraZeneca.” SEC filing
“In 2020, we entered into a Master Supply Agreement with AstraZeneca under the AstraZeneca U.S./RoW Agreement (the "AstraZeneca Master Supply Agreement") to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from Kyntra Bio in support of...” SEC filing
“Kyntra Bio has retained the rights to roxadustat in the United States of America ("U.S."), Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas Pharma Inc. ("Astellas").” SEC filing
“We have entered into commercial supply arrangements with Shanghai SynTheAll Pharmaceutical Co., Ltd. ("WuXi STA") and Catalent Pharma Solutions, LLC ("Catalent") as our primary manufacturers of roxadustat drug substance (also known as active pharmaceutical ingredient ("API")) and roxadustat drug pro...” SEC filing
“We have entered into an Evaluation Agreement with Fortis Therapeutics, Inc. ("Fortis") under which we rely, in part, on Fortis and its development partners, including University of California, San Francisco, for the continued development of FG-3246 (in conjunction with our PET biomarker).” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.